>> Download the Complete Abstract Book

NEW for this year:
HEP DART 2007 Satellite Symposium: "Toward Curative Therapies for Hepatitis C"

Selected Slide Presentations
(Click on the links below to view presentations)

State of the Art Lectures
The Changing Global Epidemiology of HBV and HCV
Kevin Fenton, Centers for Disease Control and Prevention, USA

New Insights into Hepatitis B Pathogenesis and Resistance
Stephen Locarnini, Victorian Infectious Diseases Reference Laboratory, Australia

New Insights into the HCV Replication Cycle: Lessons Learned from Novel Culture Systems
Ralf Bartenschlager, University of Heidelberg, Germany

Advances in New Models for HBV and HCV
Special Lecture
Insights into the Impact of HBV and HCV Viral Dynamics on Antiviral Therapy
Alan S. Perelson, Los Alamos National Laboratories, USA

DNA Microarray Analysis of the NS3 and NS5B Genes from Hepatitis C Genotype 1a
Infected Patients
Gustine Liu-Young, Yale University, USA

Assessment of Both Virological Response at Week 4 and at Week 12 Optimizes
Prediciton of Treatment Outcome in Patients with Chronic Hepatitis C Treated with Peginterferon Alfa-2B plus Ribavirin
Michelle Martinot-Peignoux, INSERM U-773-CRB3, France

Week 24 is the Optimal Time Point for Predicting Outcomes at 2 Years with Telbivudine
Rajender Reddy, University of Pennsylvania School of Medicine, USA

The Business of Hepatitis Antivirals
The Business of Hepatitis Antivirals: Bridging Diverse Interests
Patrick Higgins, Pharmasset, Inc., USA

Diagnosis and New Treatments for HBV and HCV
State of the Art Lecture
HCV Replicons vs. Infectious Virus Systems in Drug Discovery
Stanley M. Lemon, University of Texas Medical Branch at Galveston, USA

Population Genetics of HBV and HCV Quasispecies: Implications for Drug Development
and Drug-resistance Testing
Robert W. Shafer, Stanford University, USA

Nitazoxanide: A Potent Antiviral Agent against HCV and HBV
Brent E. Korba, Georgetown University, USA

Phase 2 Studies with Albinterferon Alfa -2b (alb-IFN) Dosed q4wk Provide Insights
into Dose Selection for Future Studies
D. Nelson, University of Florida, USA

Robust Antiviral Efficacy of a "Finger-loop" Allosteric Inhibitor of the HCV Polymerase
in HCV Infected Chimpanzees
Raffaele De Francesco, I.R.B.M. "P Angeletti," Italy

Preclinical Development of the Amphipathic DNA Polymer REP 9AC for the Treatment
of HBV Infection
Andrew Vaillant, REPLICor Inc., Canada

Inhibition of Hepatitis C Virus Replication by Octadecyloxypropyl-(S)-HPMPA in Genotype 1B and 2A Replicons
Karl Y. Hostetler, University of California, San Diego, USA

FKBP8 Plays a Crucial Role in the Replication of Hepatitis C Virus
Yoshiharu Matsuura, Osaka University, Japan 

Hepatitis B Foundation Symposium: Early Detection and Management of Cirrhosis and Hepatocellular Carcinoma
Introduction: Early Detection and Management of Cirrhosis and Hepatocellular Carcinoma
Timothy Block, Hepatitis B Foundation and Drexel University Medical College, USA

Assessment of Fibrosis: Non Biopsy Methods to Determine Hepatic Fibrosis
Nezam H. Afdhal, Harvard Medical School, USA

Screening Fibrosis: “La Révolution Française”
Thierry Poynard, Groupe Hospitalier Pitié-Salpêtrière, France

Treatment of HCC over the Past Decade: The Experience of over Four Thousand Patients in Japan
Masao Omata, University of Tokyo, Japan

Back to Top>>

Immunology & Pathogenesis
Cellular Immune Responses against Hepatitis C in Acute and Chronic Infection
Margaret J. Koziel, Harvard Medical School, USA

Broadly Neutralizing Antibodies to HCV: Definition of Epitopes and Antiviral Activity
In Vitro and In Vivo
Mansun Law, The Scripps Research Institute, USA

Innate Immune Studies in Hepatitis B: Novel Studies in Pathogenesis and Treatment
Kumar Visvanathan, Monash Institute of Medical Research, Australia

New Therapeudic Approaches I
State of the Art Lecture
HCV Entry Pathways and Implications for the Development of Entry Inhibitors
Matthew J. Evans, The Rockefeller University, USA

The Role of CD81 and Scavenger Receptor Class B Member 1 in HCV Entry
Peter Balfe, University of Birmingham, UK

Lipid Droplet is an Important Organelle for Production of Infectious Hepatitis C Virus
Kunitada Shimotohno, Keio University, Japan

The Role of Cyclophilins and Cyclophilin Inhibitors in the Replication of HCV
Rafael Crabbé, Debiopharm S.A., Switzerland

New Therapeutic Approaches II
Development of Novel Hyperglycosylated Type 1 Interferons: A Strategy to Improve PK
Performance without Loss of Biological Potency
Lawrence M. Blatt, Alios BioPharma, Inc., USA

Bioinformatics Resources Supporting the Analysis of Hepatitis C Virus
Elliot J. Lefkowitz, University of Alabama at Birmingham, USA

Potent Antiviral Activity of the Nucleoside HCV Inhibitor, R7128, in Prior IFN
Non-responders
John G. McHutchison, Duke University, USA

R1626 Demonstrates Synergistic Antiviral Effect in Combination with Peginterferon
Alfa-2a [40 KD], with or without Ribavirin, and High Barrier to Resistance Development
David Nelson, University of Florida, USA

Tenofovir DF (TDF) Showed Superior Antiviral Efficacy to Adefovir Dipivoxil (ADV) at 48 Weeks in Two Pivotal, Randomized, Double-Blind, Studies for the Treatment of HBeAg-Negative (-) and HBeAg-Positive (+) Chronic Hepatitis B (CHB):
Study 102 and Study 103
Patrick Marcellin, Hôpital Beaujon, France

Resistance to Antiviral Agents
State of the Art Lecture
Navigating Dangerous Complexities: Antiviral Strategies for Clinical Trials for Hepatitis C
Yves Benhamou, Hôpital Pitié-Salpêtrière, France

Co-infection with HIV and Other Viruses
Treatment of HBV/HIV Co-infections
Marion Peters, University of California, San Francisco, USA

Treatment of HCV in HIV-infected Individuals
Zelalem Temesgen, Mayo Clinic, USA

HCV/HIV Co-infections: Challenges from the Perspective of TAG
Tracy Swan, Treatment Action Group (TAG), USA

Pharmacology and Drug Interactions of HBV and HCV Therapeutics
State of the Art Lecture
STAT-C: Role in HCV Treatment Algorithm in 2008
John G. McHutchison, Duke University, USA

Preclinical Drug Metabolism in Viral Hepatitis Drug Discovery
Adrian S. Ray, Gilead Sciences, Inc., USA

Frontiers of Clinical Pharmacology in Hepatitis Drug Development
Charles W. Flexner, Johns Hopkins University, USA

Late Breaker Abstracts
Advancing RNAi-based Therapeutic from Discovery to Clinic
Robert Gish, California Pacific Medical Research Institute, USA
Catherine Pachuk, Nucleonics Inc., USA

State of the Art Lecture - Part II
Delta Hepatitis: Treatment Options for a Largely Neglected Disease
Michael P. Manns, Hannover Medical School, Germany

Biochemical Mechanism of Entecavir as an Antiviral Polymerase Inhibitor
Karen S. Anderson, Yale University School of Medicine, USA

Back to Top>>